326 related articles for article (PubMed ID: 4064843)
61. DNA synthesis rate and unlabeled cells with S-phase DNA content in P388 leukemic cells in vivo studied by flow cytometry and cell sorting.
Clausen OP
Cytometry; 1987 Nov; 8(6):612-7. PubMed ID: 3428043
[TBL] [Abstract][Full Text] [Related]
62. S-phase fraction, 5-bromo-2'-deoxy-uridine labelling index, duration of S-phase, potential doubling time, and DNA index in benign and malignant brain tumors.
Struikmans H; Rutgers DH; Jansen GH; Tulleken CA; van der Tweel I; Battermann JJ
Radiat Oncol Investig; 1997; 5(4):170-9. PubMed ID: 9327496
[TBL] [Abstract][Full Text] [Related]
63. Tumor radiosensitization by sustained intratumoral release of bromodeoxyuridine.
Doiron A; Yapp DT; Olivares M; Zhu JX; Lehnert S
Cancer Res; 1999 Aug; 59(15):3677-81. PubMed ID: 10446981
[TBL] [Abstract][Full Text] [Related]
64. Flow cytometric study of the type II pneumocyte cell cycle in vivo and in vitro.
Uhal BD
Cytometry; 1994 Jan; 15(1):46-52. PubMed ID: 8162824
[TBL] [Abstract][Full Text] [Related]
65. Bromodeoxyuridine amplifies the inhibitory effect of oxygen on cell proliferation.
Poot M; Schindler D; Kubbies M; Hoehn H; Rabinovitch PS
Cytometry; 1988 Jul; 9(4):332-8. PubMed ID: 2456899
[TBL] [Abstract][Full Text] [Related]
66. Tumour growth rates in squamous carcinoma of the head and neck measured by in vivo bromodeoxyuridine incorporation and flow cytometry.
Forster G; Cooke TG; Cooke LD; Stanton PD; Bowie G; Stell PM
Br J Cancer; 1992 May; 65(5):698-702. PubMed ID: 1586597
[TBL] [Abstract][Full Text] [Related]
67. Distinction between 5-bromodeoxyuridine labeled and unlabeled mitotic cells by flow cytometry.
Darzynkiewicz Z; Traganos F; Melamed MR
Cytometry; 1983 Mar; 3(5):345-8. PubMed ID: 6839883
[TBL] [Abstract][Full Text] [Related]
68. Bromodeoxyuridine incorporation into DNA of human leukemia cells is not concentration dependent.
Powell BL; Gregory BW; Kute TE; Morgan TM; Lyerly ES; Capizzi RL
Cytometry; 1990; 11(3):438-41. PubMed ID: 2340778
[TBL] [Abstract][Full Text] [Related]
69. Flow cytometry vs. Ki67 labelling index in breast cancer: a prospective evaluation of 181 cases.
Martínez-Arribas F; Núñez MJ; Piqueras V; Lucas AR; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2002; 22(1A):295-8. PubMed ID: 12017306
[TBL] [Abstract][Full Text] [Related]
70. A comparison of proliferation markers (BrdUrd, Ki-67, PCNA) determined at each cell position in the crypts of normal human colonic mucosa.
Bromley M; Rew D; Becciolini A; Balzi M; Chadwick C; Hewitt D; Li YQ; Potten CS
Eur J Histochem; 1996; 40(2):89-100. PubMed ID: 8839702
[TBL] [Abstract][Full Text] [Related]
71. Subdivision of S-phase by analysis of nuclear 5-bromodeoxyuridine staining patterns.
van Dierendonck JH; Keyzer R; van de Velde CJ; Cornelisse CJ
Cytometry; 1989 Mar; 10(2):143-50. PubMed ID: 2469556
[TBL] [Abstract][Full Text] [Related]
72. Measurement of cell kinetics in human tumours in vivo using bromodeoxyuridine incorporation and flow cytometry.
Wilson GD; McNally NJ; Dische S; Saunders MI; Des Rochers C; Lewis AA; Bennett MH
Br J Cancer; 1988 Oct; 58(4):423-31. PubMed ID: 3207597
[TBL] [Abstract][Full Text] [Related]
73. Influence of sampling time on assessment of potential doubling time.
Høyer M; Bentzen SM; Salling LN; Overgaard J
Cytometry; 1994 Jun; 16(2):144-51. PubMed ID: 7924683
[TBL] [Abstract][Full Text] [Related]
74. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake.
Higashi K; Clavo AC; Wahl RL
J Nucl Med; 1993 Mar; 34(3):414-9. PubMed ID: 8441032
[TBL] [Abstract][Full Text] [Related]
75. Heterogeneity of bromodeoxyuridine sensitivity of cultured cells from melanoma metastases.
Poot M; Hiller KH; Heimpel S; Schuster A; Köhler J; Hoehn H
Cytometry; 1995 Sep; 21(1):62-7. PubMed ID: 8529473
[TBL] [Abstract][Full Text] [Related]
76. Double labeling of S-phase murine cells with bromodeoxyuridine and a second DNA-specific probe.
Raza A; Spiridonidis C; Ucar K; Mayers G; Bankert R; Preisler HD
Cancer Res; 1985 May; 45(5):2283-7. PubMed ID: 3986772
[TBL] [Abstract][Full Text] [Related]
77. In vivo bromodeoxyuridine (BrdU)-labelling index of rat thymus: influence of different BrdU doses and exposure times as analyzed both in tissue sections and in single cell suspensions.
Carbajo S; Orfao A; Alberca V; Ciudad J; López A; Hernández LC; Carbajo-Pérez E
Anal Cell Pathol; 1995 Jan; 8(1):15-25. PubMed ID: 7734409
[TBL] [Abstract][Full Text] [Related]
78. Immediate bromodeoxyuridine labelling of unseparated human bone marrow cells ex vivo is superior to labelling after routine laboratory processing.
Jensen PO; Mortensen BT; Christensen IJ; Larsen JK
Cell Prolif; 1998 Feb; 31(1):1-7. PubMed ID: 9666814
[TBL] [Abstract][Full Text] [Related]
79. Comparative autoradiographic in vitro study of the incorporation of 3H-thymidine and 3H-uridine into the DNA and RNA of solid tumours in children.
Willnow U
Arch Geschwulstforsch; 1980; 50(8):778-84. PubMed ID: 7224820
[TBL] [Abstract][Full Text] [Related]
80. Cell cycle distribution of hypoxia and progression of hypoxic tumour cells in vivo.
Webster L; Hodgkiss RJ; Wilson GD
Br J Cancer; 1998; 77(2):227-34. PubMed ID: 9460993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
